Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)
| Financial Ratios | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Return on Equity | -8.917 | -56.68 | -11.759 | -14.313 |
| Net Profit Margin | -1,220,200 | -2,344,700 | -258,013.333 | -534,812.5 |
| Debt to Asset Ratio | 21.95 | 27.011 | 19.326 | 22.449 |
| Cash Ratio | 245.676 | 121.794 | 387.65 | 267.74 |
| Quick Ratio | 723.48 | 528.088 | 1,029.553 | 764.745 |
| Current Ratio | 723.48 | 528.088 | 1,029.553 | 764.745 |